NR2F1 and head and neck squamous cell carcinoma: Furthermore, the potential of ‘dormancy-inducing’ therapies to block or convert minimal residual disease at the level of (few) DTCs is also being considered: as a paradigm of this concept the epigenetic regulation of dormancy-inducing nuclear receptor NR2F1 with all-trans retinoic acid and azacytidine (124) or with a specific agonist (125) has been shown to induce prolonged dormancy and reduce metastatic outgrowth in head and neck squamous cell carcinoma (HNSCC).